Jason Szabo, MD, PhD

L'Actuel Medical Clinic, Canada

Disclosure(s): Gilead: Advisory board; Speaker fees, Grant/Research Support; Merck: Speaker Fees; Novo Nordisk: Advisory board; ViiV: Advisory board; Speaker fees, Grant/Research Support

Poster(s):

• (P-377) Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET